Effectiveness and Safety of Amlodipine in Newly Diagnosed Hypertensive Patients and in Previously Diagnosed Hypertensive Patients not Controlled with their Usual Treatment (NOTA Study)

Clinical Drug Investigation

Volumn 23, Issue 12, 2003, Pages 761-770

  Valcarcel Y ^a   Jimenez R ^a   Aristegui R ^b   Gil, A ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; LISINOPRIL; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; OPEN STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE;

EID: 17744407800     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323120-00001     Document Type: Article

References (37)

1. Arístegui I, Calderón A, Gómez de la Cámara J, et al. Reducción del riesgo en la hipertensión arterial asociada a factores de riesgo cardiovascular: Proyecto HYDRA. Hipertensión 2000; 17 (3): 31-42
2. Banegas JR, Villar F, Pérez C, et al. Estudio epidemioló gico de los factores de riesgo cardiovascular en la poblacion adulta de 35 a 64 años. Revista de Higiene Pública 1993; 67: 419-26
3. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275 (20): 1571-6
4. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335 (8692): 765-74
5. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease: The Framingham Heart Study. N Engl J Med 1990; 322 (23): 1635-41
6. Kannel W, D'Agostino R. Actualización de los antiguos factures de riesgo coronarios. Cardiov Risk Factors 1997; 6 (2): 86-96
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC VII report. JAMA 2003; 289 (19): 2560-71
8. Sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Int Med 1997; 157 (21): 2413-46
9. Chalmer J, MacMahon S, Mancia G, et al. World Health Organization- International Society of Hypertension Guidelines for the Management of Hypertension: Guidelines Subcommittee. J Hypertens 1999; 17 (2): 151-83
10. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting: Guidelines Sub-Committee. J Hypertens 1993; 11 (9): 905-18
11. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319 (7210): 630-5
12. Feldman RD, Campbell N, Larochelle P, et al. 1999 Canadian recommendations for the management of hypertension: Task Force for the Development of the 1999 Canadian recommendations for the management of hypertension. CMAJ 1999; 161 Suppl. 12: S1-17
13. Clavijo GA, de Clavijo IV, Weart CW. Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994; 51 (1): 59-68
14. Neaton J, Grimm RH, Prineas R, et al. Treatment of mild hypertension study: final results: Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270 (6): 713-24
15. Pessina A, Galluci M. Assessment of tolerability and efficacy of amlodipine in 9294 patients with mild or moderate essential hypertension. Clin Drug Invest 1997; 13 (1): 137-42
16. The ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288 (23): 2981-97
17. Madruga M, De Abajo FJ, Martín-Serrano G, et al. Nuevas perspectivas de la farmacovigilancia en España y en la Unión Europea. Madrid: Editores Grupo IFAS, 1998
18. Olalla JF, Alvarez C. La postcomercialización de los medicamentos en España. La farmacovigilancia a nivel internacional. En: Mateos, J. Farmacoepidemiología. La Coruña: Xunta de Galicia, 1995
19. Gil A, Jiménez R, Carrasco P, et al. Seguridad y efectividad de amlodipino en pacientes hipertensos no controlados farmacológicamente en el ámbito de la atencioie;n primaria. Hipertensión 2000; 17 (7): 18-29
20. Burns JF, Ames, RP. Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: S98-102
21. Gil A, Jiménez R, San Martín M, et al. Drug surveillance study of amlodipine in patients with hypertension not controlled with drug therapy: NORCON study. Current Therapeutic Research 2000; 61 (12): 863-70
22. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del estudio Controlpress 2001. Hipertensión 2002; 19 (9): 390-9
23. Maclean D. Combination therapy with amlodipine and captopril for resistant systemic hypertension. Am J Cardiol 1994; 73 (3): 55A-8A
24. Jensen H, Garsdal P, Davies J. Amlodipine with enalapril therapy in moderate-severe essential hypertension. J Hum Hypertens 1990; 4 (5): 541-5
25. Gabriel R, Alonso M, Bermejo F, et al. Proyecto EPICARDIAN: estudio epidemiológico sobre enfermedades y factores de riesgo cardiovascular en ancianos españoles: diseño, método y resultados preliminares. Rev Esp Geriatr Gerontol 1996; 31: 327-34
26. Rached A, Estrada R, Jaber I. Estudio epidemiológico de los factores de riesgo en Alcalá de Henares. An Med Interna 1997; 14: 226-30
27. Plans P, Tresserras R, Pardell H, et al. Epidemiologia de la hipertensión arterial en la población adulta de Cataluña. Med Clin (Barc) 1992; 98: 369-72
28. Pardell H, De Oya M, Gil M, et al. Epidemiología de los factores de riesgo vascular en la población hipertensa española. Hipertensión 1993; 10 (5): 155-60
29. Aranda P, Aranda F, Aranda P. Hipertensión arterial e hiperlipidemia. Cuadernos latinoamericanos de hipertensión. Barcelona: Ediciones Doyma, 1998: 165-75
30. Korner PI, Jennings GL. Assessment of prevalence of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16 (6): 715-23
31. Pearson AC, Gudipati C, Nagelhout D, et al. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension. J Am Coll Cardiol 1991; 17 (2): 422-30
32. Campo C, Castellanos C, Gil B, et al. Control de la hipertensión arterial en unidades de hipertensión [abstract]. El estudio CLUE. Hipertensión 2001; 18: 108
33. Barrios V, Campuzano R, Peña G, et al. Estratificación del riesgo cardiovascular en hipertensión en Atención Primaria e impacto sobre el tratamiento antihipertensivo. Estudio DIORISC. Hipertensión 2002; 19(3): 114-20
34. Sierra A, Ruilope L, Coca A, et al. Relación entre el perfil de riesgo cardiovascular y la selección y utilización de los fármacos antihipertensivos. Med Clin (Barc) 2000; 115: 41-5
35. Jiménez R. Tratamiento de la hipertensión arterial en Atención Primaria. Madrid: Tesis Doctoral, 1998
36. Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997; 10 (10 Pt 1): 1097-02
37. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25 (3): 305-13